Reveals lack of binding of CRP aptamer in biosensors, underscoring validation necessity.
Aptamer sequences are often reused in biosensors and diagnostics without independent confirmation of binding activity, even though rigorous validation requires quantitative solution-phase testing by orthogonal methods. Here, we re-examined a DNA sequence reported in 2010 to bind C-reactive protein (CRP) with a K d of 3.5 nM by surface plasmon resonance (SPR) and subsequently adopted in many CRP aptasensor studies. We tested this sequence by two orthogonal solution-phase methods and by SPR. In solution-phase assays, we found no detectable binding of the reported aptamer to native CRP. In SPR, we found that CRP binds strongly to streptavidin-containing sensor surfaces even in the absence of immobilized DNA, whereas the reported sequence produced no measurable ligand-specific SPR response under lower-background capture conditions. Thus, the originally reported affinity is best explained by surface-driven pseudoaffinity rather than true aptamer-CRP recognition. More broadly, this case does not merely add another example of aptamer nonbinding, but reveals a general route by which nonbinding aptamers can acquire apparent affinity through surface-driven pseudoaffinity and then be propagated through the biosensor literature as validated molecular recognition reagents. This study underscores the need for orthogonal solution-phase validation before aptamers are reused in biosensor development and related analytical applications.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: